Browsing by Author Simes, Robert John

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 177  next >
Issue DateTitleAuthor(s)Citation
2010Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetesBarter, Philip; Keech, Anthony (Tony); Mann, Kirsty; Simes, Robert John; Best, J; Ehnholm, Christian; Hamwood, S; Sullivan, David Richmond; Taskinen, M.; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAbility of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes, Diabetologia: clinical and experimental diabetes and metabolism, vol.53, 9,pp 1846-1855
2003Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the long-term intervention with Pravastatin in Ischaemic Disease (LIPID) StudyKirby, Adrienne; Pater, Helen; Simes, Robert John; Hunt, David; Liew, Danny; Magliano, Dianna; Sundararajan, Vijaya; Tonkin, Andrew; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAccuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the long-term intervention with Pravastatin in Ischaemic Disease (LIPID) Study, Australian and New Zealand Journal of Public Health, vol.27,(6),2003,pp 649-653
2002Adjuvant Immunotherapy of Patients with High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized TrialCoates, Alan; McCarthy, William; McMullen, A V E; Simes, Robert John; Thompson, John; Coventry,, B; Dillon, H; Grantley, G l; Hersey, Peter; Mcleod,, R; Sillar, R; School of Public Health: Public Health; Central Clinical School: Surgery; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: SurgeryAdjuvant Immunotherapy of Patients with High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial, Journal of Clinical Oncology, vol.20,(20),2002,pp 4181-4189
2014Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE CollaborationKirby, Adrienne; Mister, Rebecca; Simes, Robert John; Agnelli, Giancarlo; Becattini, Cecilia; Brighton, Timothy; Eikelboom, John; Prandoni, Paolo; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration, Circulation (Baltimore), vol.130, 13, 2014,pp 1062-1071
2014Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long - Term Coronary Events Following Myocardial Infarction or Unstable AnginaKeech, Anthony (Tony); Mann, Kristy; Simes, Robert John; Blankenberg, Stefan; Colquhoun, David; Hunt, David; Nestel, Paul; Stewart, Ralph A.H.; Sullivan, David; Thompson, Peter; Tonkin, Andrew; West, Malcolm; White, Harvey D.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAssociation of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long - Term Coronary Events Following Myocardial Infarction or Unstable Angina, Journal of the American College of Cardiology, vol.63, 4, 2014,pp 345-354
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Pavlakis, Nick; Simes, Robert John; Blondal, J; Burkes, R L; Gibbs, Peter; Jonker, D; Karapetis, Christos; Lee, U; Meharchand, J; Moore, Malcolm; O'Callaghan, Chris; Price, T.J.; Rubin, S; Shapiro, Jeremy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; Vickers, M; Zalcberg, John; Zhu, L; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreAssociation of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17, Annals of Oncology, vol.24, 4, 2013,pp 953-960
2010Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabSimes, Robert John; Arena, Sabrina; Bardelli, Alberto; Cutsem, E Van; De Roock, Wendy; Di Nicolantonio, Federica; Frattini, Milo; Jonker, Derek J.; Karapetis, Christos; Khambata-Ford, Shirin; Lamba, Simona; O'Callaghan, Chris; Piessevaux, Hubert; Sartore-Bianchi, Andrea; Siena, Salvatore; Tejpar, Sabine; Tu, D.; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials CentreAssociation of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab, JAMA: The Journal of the American Medical Association, vol.304, 16,pp 1812-1820
2011Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD studyDonoghoe, Mark; Forder, Peta; Keech, Anthony (Tony); Kritharides, Leonard; Merrifield, Alistair; Simes, Robert John; Sullivan, David; Colman, P. G.; Haapamäki, Hannu; Neil, Graham; Whiting, Malcolm; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Concord Clinical School: ANZAC Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Molecular BioscienceAssociations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD study, Diabetes Research and Clinical Practice, vol.94, 2, 2011,pp 284-290
2015Australian clinical trial activity and burden of disease: an analysis of registered trials in National Health Priority AreasAskie, Lisa; Lord, Sarah (Sally); Simes, Robert John; Hunter, Kylie; Lam, Jacquelyne; Vu, Thuyen; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreAustralian clinical trial activity and burden of disease: an analysis of registered trials in National Health Priority Areas, Medical Journal of Australia, vol.203, 2, 2015,pp 97-102
2003The benefits and costs of tamoxifen for breast cancer preventionEckermann, Simon; Martin, Andrew; Simes, Robert John; Stockler, Martin; School of Public Health: NH&MRC Clinical Trials Centre; Clinical Schools; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe benefits and costs of tamoxifen for breast cancer prevention, Australian and New Zealand Journal of Public Health, vol.27,(1),2003,pp 34-40
2012Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin CSimes, Robert John; Tebbutt, Niall; Wilson, Catherine; Zannino, Diana; Ackland, Stephen P.; Broad, A; Cassidy, J; Ganju, V.; Price, Timothy; Robinson, B; Van Hazel, Guy Arthur; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials CentreBevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C, Annals of Oncology, vol.23, 6, 2012,pp 1531-1536
2007Biases in the Identification of Risk Factor Thresholds and J-CurvesKeech, Anthony (Tony); Marschner, Ian; Simes, Robert John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreBiases in the Identification of Risk Factor Thresholds and J-Curves, American Journal of Epidemiology, vol.166,(7),2007,pp 824-831
2015Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker studyHague, Wendy; Keech, Anthony (Tony); Kirby, Adrienne; Simes, Robert John; Sullivan, David; Blankenberg, Stefan; Colquhoun, David; Funke-Kaiser, Anne; Hunt, David; Nestel, P; Stewart, Ralph; Thompson, Peter; Tonkin, Andrew; West, Malcolm; White, Harvey; Zeller, Tanja; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreBiomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study, International Journal of Cardiology, vol.201, N/A, 2015,pp 499-507
2005Brain natriuretic peptide: a predictor of cardiovascular outcome in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) studyKirby, Adrienne; Pollicino, Christine; Simes, Robert John; Blankenberg, Stefan; Nestel, P; Tonkin, A; West, M J; White, H D; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials CentreBrain natriuretic peptide: a predictor of cardiovascular outcome in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study, European Heart Journal (English Edition), vol.26, Suppl 1,pp 718-718
2007Bs06 patient-rated outcome measures were more sensitive than clinician-rated measures at distinguishing the effects of sentinel node biopsy and axillary clearance in the snac trialGill, Peter; Simes, Robert John; Smith, Michaella; Sourjina, Tatiana; Stockler, Martin; Wetzig, Neil; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Medical Sciences: Physiology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreBs06 patient-rated outcome measures were more sensitive than clinician-rated measures at distinguishing the effects of sentinel node biopsy and axillary clearance in the snac trial, ANZ Journal of Surgery, vol.77,(Suppl. 1),2007,pp A2-A2
2008Can self-rated health scores be used for risk prediction in patients with type 2 diabetes?Clarke, Philip; Hayes, Alison; Keech, Anthony (Tony); Simes, Robert John; Drury, P; Glasziou, Paul; School of Public Health: Public Health; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCan self-rated health scores be used for risk prediction in patients with type 2 diabetes?, Diabetes Care, vol.31, 4, 2008,pp 795-797
2010Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study.Gebski, Val; Simes, Robert John; Stockler, Martin; Zannino, Diana; Ackland, Stephen P.; Broad, Adam; Chua, Yu Jo; Cummins, Michelle; Cunningham, David; Forgeson, Garry; Ganju, Vinod; Price, Timothy; Robinson, Bridget; Saunders, M; Tebbutt, Niall C; van Hazel, Guy; Wilson, Kate; Zalcberg, J; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCapecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study., Journal of Clinical Oncology (Online), vol.28, 19,pp 3191-3198
2011Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancerBrown, Christopher; Gebski, Val; Gurney, Howard; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Bacon, M; Donadello, Nicoletta; Friedlander, Michael; Maenpaa, J; Meier, W; Petru, E; Pujade-Lauraine, Eric; Reed, N; Sorio, R; Tulunay, G; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCarboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer, British Journal of Cancer, vol.105, 3, 2011,pp 360-365
2007Cetuximab for the Treatment of Colorectal CancerSimes, Robert John; Zalcberg, John; Au, Heather Jane; Berry, Scott R.; et, al; Jonker, Derek J.; Karapetis, Christos (Chris); Krahn, Marianne; O’Callaghan, Chris J.; Price, Timothy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCetuximab for the Treatment of Colorectal Cancer, New England Journal of Medicine, vol.357,(20),2007,pp 2040-2048
2013Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease studyBarnes, Elizabeth; Keech, Anthony (Tony); Marschner, Ian (Colin); Simes, Robert John; Sullivan, David; Blankenberg, Stefan; Colquhoun, David; Hunt, David; Nestel, Paul; Stewart, Ralph A.H.; Thompson, Peter; Tonkin, Andrew; West, Malcolm; White, Harvey D.; Zeller, Tanja; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreChanges in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study, Journal of the American Heart Association, vol.2, 5, 2013,pp 1-12